Eohilia denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for eohilia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why This Denial Happens — and Why It Is Likely Incorrect

Eohilia (budesonide oral suspension) received FDA approval specifically for eosinophilic esophagitis (EoE). An Aetna denial citing "not FDA-approved" is therefore almost always a coding or administrative error — the drug is, in fact, FDA-approved for this condition — rather than a genuine regulatory finding. Common causes include: the claim was submitted under an incorrect diagnosis code, the pharmacy used a billing code the system did not recognize as the brand, or Aetna's utilization-management platform confused Eohilia with an older compounded budesonide preparation that did not go through the standard FDA approval pathway.

Because this denial is based on a factual error, it is among the most straightforward to reverse.

## Your Federal Appeal Rights

• Internal appeal (ACA / ERISA §503): You have a right to a full-and-fair review explaining exactly why the plan concluded the drug is not FDA-approved. Employer-sponsored plans must follow ERISA §503 procedures; ACA §2719 governs non-grandfathered individual and group market plans.
• External review (ACA §2719): After exhausting internal appeals, an independent IRO can review whether the denial is consistent with accepted standards. An incorrect FDA-approval determination is precisely the type of factual and clinical error IROs are empowered to overturn.
• Expedited pathway: If your health would be seriously jeopardized by waiting, request expedited review at both the internal and external stages.
• Deadline: External review requests are typically due within approximately four months of the final internal denial — verify the exact date on your denial letter.

## The Concrete Appeal Process

1. Obtain the complete denial explanation identifying the specific basis for the "not FDA-approved" determination. 2. Download the current FDA approval letter and prescribing information for Eohilia directly from FDA.gov — this is your primary rebuttal document. 3. Verify that the pharmacy submitted the correct NDC code and diagnosis code (ICD-10 for EoE) with the claim. 4. Submit a written internal appeal attaching the FDA approval documentation and, if applicable, a corrected claim with accurate codes. 5. Include a prescriber letter confirming the on-label indication and the patient's confirmed EoE diagnosis. 6. If Aetna does not reverse on internal appeal, file for external review.

## Documentation to Gather

• FDA approval documentation: The current FDA label for Eohilia (available on FDA.gov), confirming the approved indication.
• Prescription and claim details: NDC number, ICD-10 diagnosis code, and prescribing information as submitted to the pharmacy and insurer.
• Diagnosis confirmation: Specialist notes and biopsy/endoscopy reports establishing the EoE diagnosis matching the on-label indication.
• Prescriber letter: A brief letter from the treating specialist confirming the on-label use and the patient's diagnosis.

## Criteria-Mapping Strategy

The core argument is simple: cite the FDA approval letter and label, confirm the submitted diagnosis matches the approved indication, verify the billing codes were correct, and present this evidence in a clear one-page summary. Do not allow the insurer to conflate FDA-approved Eohilia with older compounded budesonide preparations — explicitly distinguish the two in your appeal letter if there is any ambiguity.